Neurofibromatosis Type 1 Brain Tumor Genetic Risk

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

176 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-10-31

Study Completion Date

2017-05-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will analyze DNA samples to determine associations between maternal and offspring genetic factors and pediatric brain tumor development in children with Neurofibromatosis Type 1. Participating families (mother, father, child) will be asked to complete a short questionnaire and provide DNA samples (either saliva or blood). The information gained from your participation may one day help doctors develop strategies to reduce brain tumor risk in individuals with NF1. Please note: there is no therapy associated with this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children

NCT00010114

Central Nervous System Embryonal Neoplasm

COMPLETED

Genetic Study of Brain Tumors in Young Children

NCT00010101

Central Nervous System Tumor, Pediatric

TERMINATED

Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs

NCT01218152

Neurofibromatosis Type 1

UNKNOWN

Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)

NCT00111384

Neurofibromatosis Type 1 Legius Syndrome

COMPLETED

Genetic Evaluation of NF1 and Scoliosis Patients

NCT01776125

Neurofibromatosis 1 Scoliosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The prenatal period is a developmentally vulnerable time point during which environmental conditions, including nutrition, can have life-long impacts on health.1,2 This is particularly relevant to many childhood cancers that are thought to initiate during pregnancy.3 As a consequence, there has been intense interest in whether prenatal exposures can modulate childhood cancer risk.4-6 It is important to recognize that both maternal and offspring genetic factors including those in nutritional pathways may play an important role in pediatric cancer risk through their effect on the child's exposure to nutrients important in development during the prenatal period. The purpose of this research study is to evaluate whether there are any maternal or offspring genetic factors in the folate pathway that may contribute to the development of brain tumors in children with Neurofibromatosis Type 1 through analysis of DNA samples collected from families.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neurofibromatosis Type 1 Pediatric Brain Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Family

Families with a child with Neurofibromatosis Type 1 who has been diagnosed with a brain tumor.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pediatric participant (born during 1994-2012) with NF1 and diagnosed with a brain tumor
* Biological mother or father (or full sibling if mother or father is unable to participate) able to participate
* All family members (pediatric participant, biological mother, and biological father or full sibling) must be willing to contribute a blood or saliva sample
* ability to understand consent forms

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No